Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AHT956 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| AHT956 | DRUG | - |
Inclusion Criteria: * Healthy male and female subjects age 18 to 45 years of age included, and in good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at screening. * Vital signs must be within the following ranges: oral body ...
AHT956 is an investigational small molecule being studied in healthy volunteers. It is not approved for any disease and is in Phase 1 clinical development. The only completed trial explored its safety, tolerability, pharmacokinetics, and pharmacodynamics after oral administration in healthy subjects.
AHT956 is being developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker NVS. The company sponsored the Phase 1 study of this investigational small molecule in healthy volunteers.
AHT956 is in Phase 1 clinical development. A single Phase 1 study has been completed, involving 42 healthy participants in Switzerland. The drug remains investigational and has not been approved by regulatory authorities for any use.
AHT956 has one completed clinical trial, registered as NCT00410228. The study, titled "Study to Explore the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AHT956 in Healthy Subjects," enrolled 42 healthy adults aged 18 years and older in Switzerland.
AHT956 is not FDA approved. It is an investigational drug that has completed a Phase 1 trial in healthy volunteers. The drug is still in clinical development and has not been authorized for marketing or use in any patient population.